SURVYR

A

Agilent Technologies, Inc.
$177.49
+$1.53 (0.87%)Oct 27 close
Health CareS&P 500 CompareTechnicals
1M3M6M1Y2Y
-26%-13%-1%+11%+23%Oct 2025Oct 2026Apr 202652w high $179.1052w low $108.35
ASPY
Wall St. Highest PT $200.00 (+12.7%) Wall St. Avg PT $182.05 (+2.6%)
$110$134$158$182$206POC $136Hi $200Avg $182
Underwater Drawdown %Max DD -29.7%Current -0.1%
0.0%-29.7%
Relative Strength vs SPY+8.5% vs SPYOutperforming
+37%0%-37%
1W
+$4.48 (2.59%)
1M
+$4.96 (2.87%)
3M
+$37.16 (26.48%)
6M
+$63.01 (55.04%)
YTD
+$42.43 (31.42%)
1Y
+$31.99 (21.99%)

Chart

Loading live chart…

Ratings & dials

1m · 5m · 15m · 1h · 4h · 1D

Analyst & Morningstar ratings

Consensus · Targets · Morningstar
Wall Street analyst consensus
SellHoldStrong Buy
Buy
22 analysts · mean score 1.77
1 = Strong Buy · 5 = Sell
Strong Buy314%
Buy1255%
Hold732%
Underperform00%
Sell00%
Wall Street consensus
Analyst price targets
Current price$177.49
Average target$182.05
+$4.56 (+2.6%) upsideaverage target vs current price
CurrentAverageMedian
Low$155.00
Median$185.00
High$200.00
12-month Wall Street target range
Recent analyst rating changes · 30
Initiated
2026-10-26 · Deutsche Bank started covering A at Buy
Reiterated
2026-10-13 · TD Cowen reiterated Buy on A
Reiterated
2026-10-13 · Morgan Stanley reiterated Overweight on A
Reiterated
2026-10-07 · Barclays reiterated Overweight on A
Reiterated
2026-08-28 · Wells Fargo reiterated Overweight on A
Reiterated
2026-08-27 · Stifel reiterated Buy on A
All analyst rating changes ›

Third-party ratings, not SURVYR.'s views.

Key stats & company

Market value$50.0B
P/E (last 12 months)35.0
P/E (next 12 months, estimated)26.4
52-week range$108.35 – $179.10
Revenue growth (latest quarter vs a year ago)+8.1%
Dividend yield0.58%
Analyst consensusBuy (20)
Average analyst price target$182.05 (+3%)

What they do

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems.

Healthcare · Diagnostics & Research
Valuation and fundamentals

Valuation & fundamentals

Loading the valuation from SEC filings…

For information only · Important disclosures

Grades vs sector

Momentum
51st percentile in sector
C+
12-1 return: +18.4%
Percentile within its GICS sector across the S&P 1500.
Growth
48th percentile in sector
C
Revenue growth (YoY): +8.1%
Percentile within its GICS sector across the S&P 1500.
Value
22nd percentile in sector
D
Forward E/P: 3.9% · EBITDA/EV: 4.1%
Percentile within its GICS sector across the S&P 1500.
Profitability
78th percentile in sector
B+
Profit margin: +19.5% · Return on equity: +21.0%
Percentile within its GICS sector across the S&P 1500.
Revisions
Not enough data yet
–
EPS estimate change, 30 days (current FY): –
30-day change in analysts' current-year EPS estimate; graded across covered stocks.

Systematic Models

Not held by any of our 7 live models right now.

Quality Growth
Outside this model's universe or screens
 Momentum Top 15
ranked 179 of 499 · 12-month momentum 20.4%
 Momentum Blend
Not in the current book
 New Highs Growth
Outside this model's universe or screens
 SURVYR. Barbell Momentum & T-Bill Shield
Outside this model's universe or screens
 SURVYR. Physical AI Grid & Power
Outside this model's universe or screens
 SURVYR. Long Book
Not in the current book

Earnings & events

A earningsNext report in 28 days
Next report
Wed Nov 25, 2026Time not confirmed
EPS consensus$1.73 range $1.71–$1.74
Revenue consensus$2.0B 17 analysts
Last 4 quarters · EPS vs estimate
Aug 26, 2026$1.62est $1.49+9.0%Above estimates
May 27, 2026$1.49est $1.41+5.8%Above estimates
Feb 25, 2026$1.36est $1.37−0.6%In line with estimates
Nov 24, 2025$1.59est $1.58+0.4%In line with estimates

In line = within 1% of the estimate.

Source: Yahoo Finance · refreshed 2026-10-27 18:23:26 ET
24-1125-0225-0525-0825-1126-0226-0526-080.001.62
EstimateActual (beat)Actual (miss)

Quarterly revenue

QuarterRevenueYoY
2026-07-31$1.9B+8.1%
2026-04-30$1.8B–
2026-01-31$1.8B–
2025-10-31$1.9B–
2025-07-31$1.7B–

Recent dividends

2026-10-06: $0.255 · 2026-06-30: $0.255 · 2026-03-31: $0.255 · 2026-01-06: $0.255 · 2025-09-30: $0.248 · 2025-07-01: $0.248 · 2025-04-01: $0.248 · 2024-12-31: $0.248

News & catalysts

More news
First Trust Capital Strength (FTCS) Buys $155.3 Million More ACGL on Friday
GuruFocus.com · Oct 20
29 ETFs Add to Agilent Technologies (A) on Oct. 16
GuruFocus.com · Oct 20
Immuno-Oncology Diagnostics Market to Reach $11.1B by 2030 as Checkpoint Inhibitor and Cell Therapy Pipelines Drive Demand for Companion Tests
GlobeNewswire · Oct 16
Rating changes
Initiated
2026-10-26 · Deutsche Bank started covering A at Buy
Reiterated
2026-10-13 · TD Cowen reiterated Buy on A
Reiterated
2026-10-13 · Morgan Stanley reiterated Overweight on A
Reiterated
2026-10-07 · Barclays reiterated Overweight on A
Reiterated
2026-08-28 · Wells Fargo reiterated Overweight on A
Reiterated
2026-08-27 · Stifel reiterated Buy on A

Third-party analyst actions, not SURVYR.'s views. All rating changes

Insider trades
Dolsten Mikael
Director · 2026-09-04
Sell
$96.0K
None
None · None
Sell
–

Stats refreshed 2026-10-27 18:23:26 ET from Yahoo Finance (yfinance). "–" means the data isn't available. Refresh now

Morning Brief (8 AM ET) & Market Close (4:30 PM ET), weekdays

Indexes, sectors, biggest movers, rates, top news, SURVYR. model changes and what's ahead. Free, two short emails each weekday.

Editions

Free. Not investment advice. Unsubscribe anytime.

SURVYR

Free to use. No card, no ads, no auto-renew.

Systematic research · Not investment advice · Hypothetical unless marked Live · Data: Yahoo Finance (15-min delayed), SEC EDGAR, House Clerk · Important disclosures · Contact desk@coteau.app

How it worksOur promiseTermsPrivacyData statusSend feedback
Coteau 0.9 · Oct 21, 2026